| Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial A Sartore-Bianchi, F Pietrantonio, S Lonardi, B Mussolin, F Rua, ... Nature Medicine 28 (8), 1612-1618, 2022 | 112 | 2022 |
| Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label … C Antoniotti, D Rossini, F Pietrantonio, A Catteau, L Salvatore, S Lonardi, ... The Lancet Oncology 23 (7), 876-887, 2022 | 98 | 2022 |
| The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors F Corti, S Lonardi, R Intini, M Salati, E Fenocchio, C Belli, B Borelli, ... European journal of cancer 150, 155-167, 2021 | 62 | 2021 |
| Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers G Fucà, R Cohen, S Lonardi, K Shitara, ME Elez, M Fakih, J Chao, ... Journal for immunotherapy of cancer 10 (2), 2022 | 57 | 2022 |
| LBA20 FOLFOXIRI plus bevacizumab (bev) plus atezolizumab (atezo) versus FOLFOXIRI plus bev as first-line treatment of unresectable metastatic colorectal cancer (mCRC) patients … C Cremolini, D Rossini, C Antoniotti, F Pietrantonio, S Lonardi, ... Annals of Oncology 32, S1294-S1295, 2021 | 36 | 2021 |
| Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy G Fucà, A Spagnoletti, M Ambrosini, F De Braud, M Di Nicola ESMO open 6 (1), 100046, 2021 | 28 | 2021 |
| Systemic treatment of patients with gastrointestinal cancers during the COVID-19 outbreak: COVID-19-adapted recommendations of the National Cancer Institute of Milan F Pietrantonio, F Morano, M Niger, S Corallo, M Antista, A Raimondi, ... Clinical Colorectal Cancer 19 (3), 156-164, 2020 | 21 | 2020 |
| Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint … G Fucà, F Corti, M Ambrosini, R Intini, M Salati, E Fenocchio, P Manca, ... Journal for Immunotherapy of Cancer 9 (4), 2021 | 19 | 2021 |
| Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal … P Manca, S Corallo, S Lonardi, G Fucà, A Busico, AG Leone, F Corti, ... British Journal of Cancer 126 (3), 449-455, 2022 | 18 | 2022 |
| Negative Ultraselection of Patients With RAS/BRAF Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy G Randon, G Maddalena, MM Germani, CC Pircher, P Manca, F Bergamo, ... JCO Precision Oncology 6, e2200037, 2022 | 17 | 2022 |
| EGFR Amplification in Metastatic Colorectal Cancer G Randon, R Yaeger, JF Hechtman, P Manca, G Fucà, H Walch, J Lee, ... JNCI: Journal of the National Cancer Institute 113 (11), 1561-1569, 2021 | 16 | 2021 |
| Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancer G Mazzoli, R Cohen, S Lonardi, F Corti, E Elez, M Fakih, P Jayachandran, ... European Journal of Cancer 172, 171-181, 2022 | 15 | 2022 |
| COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study F Nichetti, M Bini, M Ambrosini, A Ottini, A Rametta, R Leporati, D Polastri, ... ESMO open 5 (Suppl 3), 2020 | 15 | 2020 |
| Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild … R Moretto, D Rossini, I Capone, A Boccaccino, F Perrone, E Tamborini, ... Clinical Colorectal Cancer 20 (4), 314-317, 2021 | 14 | 2021 |
| Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors F Pietrantonio, S Lonardi, F Corti, G Infante, ME Elez, M Fakih, ... Journal for immunotherapy of cancer 9 (8), 2021 | 14 | 2021 |
| CEA increase as a marker of disease progression after first-line induction therapy in metastatic colorectal cancer patients. A pooled analysis of TRIBE and TRIBE2 studies R Moretto, D Rossini, V Conca, S Lonardi, C Rasola, C Antoniotti, ... British Journal of Cancer 125 (6), 839-845, 2021 | 13 | 2021 |
| Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors R Lobefaro, S Rota, L Porcu, C Brunelli, S Alfieri, E Zito, I Taglialatela, ... ESMO open 7 (2), 100457, 2022 | 10 | 2022 |
| ALK Inhibitors in Patients With ALK Fusion–Positive GI Cancers: An International Data Set and a Molecular Case Series M Ambrosini, M Del Re, P Manca, A Hendifar, A Drilon, G Harada, ... JCO Precision Oncology 6 (1), e2200015, 2022 | 9 | 2022 |
| Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy? M Ambrosini, G Fucà, M Duca, S Damian, F De Santis, F Corti, S Cresta, ... Critical Reviews in Oncology/Hematology 169, 103532, 2022 | 8 | 2022 |
| Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint … P Manca, F Corti, R Intini, G Mazzoli, R Miceli, MM Germani, F Bergamo, ... European Journal of Cancer 187, 15-24, 2023 | 7 | 2023 |
